ArticleProceedings of the National Academy of Sciences of the United States of America2006
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 374 citations in OpenAlex.
- Scalable generation of pure CD103Myeloid cells · 2026Article
- DNGR-1 signalling limits dendritic cell activation for optimal antigen cross-presentation.The EMBO journal · 2025Article
- Article
- Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: advances and challenges.Frontiers in immunology · 2025Review
- Mannan-decorated STING-activating vaccine carrier for spatial coordinative stimulating antigen-specific immune responses.Fundamental research · 2025Article
- Protocol to study ex vivo T cell priming by conventional dendritic cells from the mouse spleen.STAR protocols · 2024Article
- Efferocytosis in dendritic cells: an overlooked immunoregulatory process.Frontiers in immunology · 2024Review
- A secreted Tapasin isoform impairs cytotoxic T lymphocyte recognition by disrupting exogenous MHC class I antigen presentation.Frontiers in immunology · 2024Article
- Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming.International journal of molecular sciences · 2023Review
- The evolving biology of cross-presentation.Seminars in immunology · 2023Review
- Transcriptional regulation of dendritic cell development and function.Frontiers in immunology · 2023Review
- A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2022Article
- Endocytic membrane repair by ESCRT-III controls antigen export to the cytosol during antigen cross-presentation.Cell reports · 2022Article
- Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.Cell reports. Medicine · 2022Article
- Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies.RSC advances · 2022Review
- SMRT and NCoR1 fine-tune inflammatory versus tolerogenic balance in dendritic cells by differentially regulating STAT3 signaling.Frontiers in immunology · 2022Article
- Article
- Virus-Mimic mRNA Vaccine for Cancer Treatment.Advanced therapeutics · 2021Article
- Specialized transendothelial dendritic cells mediate thymic T-cell selection against blood-borne macromolecules.Nature communications · 2021Article
- Tocilizumab Induces IL-10-Mediated Immune Tolerance in Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2021Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Mouse spleens contain three populations of conventional (CD11c(high)) dendritic cells (DCs) that play distinct functions. The CD8(+) DC are unique in that they can present exogenous antigens on their MHC class I molecules, a process known as cross-presentation. It is unclear whether this special ability is because only the CD8(+) DC can capture the antigens used in cross-presentation assays, or because this is the only DC population that possesses specialized machinery for cross-presentation. To solve this important question we examined the splenic DC subsets for their ability to both present via MHC class II molecules and cross-present via MHC class I using four different forms of the model antigen ovalbumin (OVA). These forms include a cell-associated form, a soluble form, OVA expressed in bacteria, or OVA bound to latex beads. With the exception of bacterial antigen, which was poorly cross-presented by all DC, all antigenic forms were cross-presented much more efficiently by the CD8(+) DC. This pattern could not be attributed simply to a difference in antigen capture because all DC subsets presented the antigen via MHC class II. Indeed, direct assessments of endocytosis showed that CD8(+) and CD8(-) DC captured comparable amounts of soluble and bead-associated antigen, yet only the CD8(+) DC cross-presented these antigenic forms. Our results indicate that cross-presentation requires specialized machinery that is expressed by CD8(+) DC but largely absent from CD8(-) DC. This conclusion has important implications for the design of vaccination strategies based on antigen targeting to DC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.